Clinical translation of a PSMA inhibitor for 99m Tc-based SPECT-Reference-Cited by-同舟云学术

Clinical translation of a PSMA inhibitor for 99m Tc-based SPECT

Published:2017-05 Issue: Volume:48 Page:36-44
ISSN:0969-8051
Container-title:Nuclear Medicine and Biology
language:en
Short-container-title:Nuclear Medicine and Biology

Author:

Ferro-Flores Guillermina,Luna-Gutiérrez Myrna,Ocampo-García Blanca,Santos-Cuevas Clara,Azorín-Vega Erika,Jiménez-Mancilla Nallely,Orocio-Rodríguez Emmanuel,Davanzo Jenny,García-Pérez Francisco O.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Molecular Medicine

Reference22 articles.

1. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises;Santoni;J Biol Regul Homeost Agents,2013

2. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer;Benešová;J Nucl Med,2015

3. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-Centre study;Ahmadzadehfar;EJNMMI Res,2015

4. [177Lu]lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer;Kratochwil;Eur J Nucl Med Mol Imaging,2015

5. Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy;Baum;J Nucl Med,2016

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response to 223RaCl2 or 177Lu-iPSMA treatment in bone metastases due to castration-resistant prostate cancer as a function of absorbed dose;Radiation Physics and Chemistry;2024-09

2. Development of freeze-dried kit for the preparation of [ 99m Tc]Tc-HYNIC-ALUG: A potential agent for imaging of prostate specific membrane antigen;IRAN J NUCL MED;2024

3. Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of^99mTc and¹⁸⁸Re Theranostic Agents for Prostate Cancer;Journal of Nuclear Medicine;2024-06-06

4. 99mTc-labeled FAPI compounds for cancer and inflammation: from radiochemistry to the first clinical applications;EJNMMI Radiopharmacy and Chemistry;2024-05-02

5. Free TcO4 − in 99mTc-PSMA Scan;Clinical Nuclear Medicine;2024-04-30